ENDRA LIFE SCIENCES INC (NDRA) Stock Price, Forecast & Analysis
USA - NASDAQ:NDRA - US29273B5003 - Common Stock
NDRA Key Statistics, Chart & Performance
The current stock price of NDRA is 5.49 USD. In the past month the price decreased by -19.37%. In the past year, price decreased by -13.78%.
NDRA Latest News, Press Relases and Analysis
NDRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.17 | 218.64B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.42 | 205.00B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.2 | 149.49B | ||
| SYK | STRYKER CORP | 26.83 | 135.11B | ||
| IDXX | IDEXX LABORATORIES INC | 55.94 | 56.43B | ||
| BDX | BECTON DICKINSON AND CO | 12.57 | 51.97B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.47 | 48.99B | ||
| RMD | RESMED INC | 25.22 | 36.44B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.96 | 33.45B | ||
| PODD | INSULET CORP | 70.36 | 22.63B | ||
| DXCM | DEXCOM INC | 29.68 | 21.65B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.92 | 17.50B |
Related stock screener links
About NDRA
Company Profile
ENDRA Life Sciences, Inc. engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. The company is headquartered in Ann Arbor, Michigan and currently employs 21 full-time employees. The company went IPO on 2017-06-28. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
Company Info
ENDRA LIFE SCIENCES INC
3600 Green Ct Ste 350
Ann Arbor MICHIGAN 48105 US
CEO: Francois Michelon
Employees: 21
Phone: 17343350468
ENDRA LIFE SCIENCES INC / NDRA FAQ
What does NDRA do?
ENDRA Life Sciences, Inc. engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. The company is headquartered in Ann Arbor, Michigan and currently employs 21 full-time employees. The company went IPO on 2017-06-28. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
What is the stock price of ENDRA LIFE SCIENCES INC today?
The current stock price of NDRA is 5.49 USD. The price increased by 5.17% in the last trading session.
Does NDRA stock pay dividends?
NDRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of NDRA stock?
NDRA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the next earnings date for NDRA stock?
ENDRA LIFE SCIENCES INC (NDRA) will report earnings on 2025-11-13.
What is the ownership structure of ENDRA LIFE SCIENCES INC (NDRA)?
You can find the ownership structure of ENDRA LIFE SCIENCES INC (NDRA) on the Ownership tab.
NDRA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NDRA. When comparing the yearly performance of all stocks, NDRA turns out to be only a medium performer in the overall market: it outperformed 56.12% of all stocks.
NDRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NDRA. While NDRA seems to be doing ok healthwise, there are quite some concerns on its profitability.
NDRA Financial Highlights
Over the last trailing twelve months NDRA reported a non-GAAP Earnings per Share(EPS) of -20.8. The EPS increased by 96.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -312.19% | ||
| ROE | -594.98% | ||
| Debt/Equity | 0 |
NDRA Forecast & Estimates
7 analysts have analysed NDRA and the average price target is 38.76 USD. This implies a price increase of 606.01% is expected in the next year compared to the current price of 5.49.